Innate Pharma
IPHA
9 hedge funds and large institutions have $731K invested in Innate Pharma in 2024 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and closing their positions.
103% more capital invested
Capital invested by funds: $361K → $731K (+$370K)
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
13% more funds holding
Funds holding: 8 → 9 (+1)
0.15% more ownership
Funds ownership: 0.16% → 0.31% (+0.15%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ETC
Exchange Traded Concepts
Oklahoma City,
Oklahoma
|
+$173K |
| 2 |
Optiver Holding
Amsterdam,
Netherlands
|
+$125K |
| 3 |
Jane Street
New York
|
+$38.1K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$168 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$5.84K |
| 2 |
Millennium Management
New York
|
-$3.73K |
IPHA Hedge Fund Activity: Q1 2024 in Review
9 of the 6,961 institutional investors tracked by Wall St. Rank reported a position in Innate Pharma (IPHA) for Q1 2024, worth a combined $731K — up 103% from $361K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new IPHA positions and 0 closed out — a net gain of 1 holder — while 3 added to existing stakes and 2 trimmed.
The largest buyer was Exchange Traded Concepts, adding an estimated $173K. The largest seller was Morgan Stanley, cutting an estimated $5.84K.
- 9 institutional investors held Innate Pharma (IPHA) as of Q1 2024, up from 8 in Q4 2023.
- Funds reported $731K of Innate Pharma stock for Q1 2024, up 103% quarter-over-quarter.
- 1 fund opened new Innate Pharma positions in Q1 2024 and 0 closed out, a net change of +1 holder.
- The largest Innate Pharma buyer in Q1 2024 was Exchange Traded Concepts, an estimated $173K added.
- The largest Innate Pharma seller in Q1 2024 was Morgan Stanley, an estimated $5.84K sold.
Based on aggregated 13F filings for Q1 2024.